High-dose treatment of cathepsin B-activatable doxorubicin prodrug nanoparticles that induce tumor-specific immunogenic cell death for immunotherapy of melanoma with minimal systemic toxicity

Yoojeong Oh , Jinseong Kim , Nayeon Shim , Hyeonji Yoo , Hoyeon Lee , Yumin Jeong , Jagyeong Goo , Jeongyeon Lee , Mihee Jo , Hanhee Cho , Kwangmeyung Kim

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101123

PDF (3715KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101123 DOI: 10.1016/j.ajps.2026.101123
Research Article
research-article
High-dose treatment of cathepsin B-activatable doxorubicin prodrug nanoparticles that induce tumor-specific immunogenic cell death for immunotherapy of melanoma with minimal systemic toxicity
Author information +
History +
PDF (3715KB)

Abstract

Highly potent chemotherapy provides rapid therapeutic efficacy in melanoma, but is often limited by drug resistance, off-target toxicity, and systemic toxicity. Combination therapy with chemotherapy and immunotherapy has attracted much attention but still faces challenges such as inconsistent immune responses and systemic toxicity. To address these limitations, we developed cathepsin B-activatable doxorubicin (DOX) prodrug nanoparticles (CatB-NPs) for inducing tumor-specific immunogenic cell death (ICD), while minimizing off-target toxicity in normal tissues with low cathepsin B expression. The cathepsin B- activatable DOX prodrug was synthesized by conjugating the cathepsin B-cleavable peptide (FRRL) to DOX, yielding FRRL-DOX. The amphiphilic FRRL-DOX formed stable nanoparticles (163.6 ± 13.5 nm) through intermolecular hydrophobic interaction and π- π stacking. In melanoma cells overexpressing cathepsin B, CatB-NPs effectively induced cancer cell- specific ICD, while sparing normal cells and immune cells. When CatB-NPs-treated B16F10 cells were co-cultured with immune cells, CatB-NPs enhanced the phagocytic activity of macrophages and induced the maturation of dendritic cells (DCs). In melanoma models, CatB-NPs passively accumulated at tumor tissues through the enhanced permeability and retention effect and were selectively activated by intratumoral cathepsin B, enabling high- dose treatment that induced robust ICD. Importantly, combination therapy with CatB-NPs and anti-PD-L1 antibody enhanced ICD, DC maturation and T-cell activation, resulting in complete tumor regression in 50% of treated mice by converting the immunosuppressive tumor environment into an immune-responsive state. In a lung metastasis model, high- dose CatB-NPs with anti-PD-L1 also suppressed metastatic burden without systemic toxicity, supporting their potential as a safe and effective chemo-immunotherapy for melanoma.

Keywords

Cathepsin B-activatable prodrug / Doxorubicin / Melanoma / Immunogenic cell death / Immune checkpoint blockade / Chemo-immunotherapy

Cite this article

Download citation ▾
Yoojeong Oh, Jinseong Kim, Nayeon Shim, Hyeonji Yoo, Hoyeon Lee, Yumin Jeong, Jagyeong Goo, Jeongyeon Lee, Mihee Jo, Hanhee Cho, Kwangmeyung Kim. High-dose treatment of cathepsin B-activatable doxorubicin prodrug nanoparticles that induce tumor-specific immunogenic cell death for immunotherapy of melanoma with minimal systemic toxicity. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101123 DOI:10.1016/j.ajps.2026.101123

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Zhou L, Zhong Y, Han L, Xie Y, Wan M. Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990-2021. Sci Rep 2025; 15: 5996.

[2]

Fateeva A, Eddy K, Chen S. Current state of melanoma therapy and next steps: battling therapeutic resistance. Cancers (Basel) 2024; 16: 1571.

[3]

Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K, et al. Resistance to molecularly targeted therapies in melanoma. Cancers (Basel) 2021; 13: 230.

[4]

Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17: 6958-62.

[5]

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022; 40: 127-37.

[6]

Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 2021; 11: 5365-86.

[7]

Ghiringhelli F, Rébé C. Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: from basic science to clinical application. Immunol Rev 2024; 321: 335-49.

[8]

Bezu L, Gomes-da-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol 2015; 6: 187.

[9]

Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, et al. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial. JAMA Oncol 2020; 6: 1778-82.

[10]

Wessely A, Steeb T, Berking C, Heppt MV. How neural crest transcription factors contribute to melanoma heterogeneity, cellular plasticity, and treatment resistance. Int J Mol Sci 2021; 22: 5761.

[11]

Baronzio G, Parmar G, Baronzio M. Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid. Front Oncol 2015; 5: 165.

[12]

Porrata LF, Adjei AA. The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours. Br J Cancer 2001; 85: 484-9.

[13]

Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 2006; 17: 1479-88.

[14]

Amiri M, Molavi O, Sabetkam S, Jafari S, Montazersaheb S. Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds. Cancer Cell Int 2023; 23: 200.

[15]

Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol 2015; 63: 114-21.

[16]

Hoek J, Bloemendal KM, van der Velden LA, van Diessen JN, van Werkhoven E, Klop WM, et al. Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas. Cancers (Basel) 2016; 8: 21.

[17]

Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10: 337.

[18]

Teixeira AAS, Biondo LA, Silveira LS, Lima EA, Batatinha HA, Diniz TA, et al. Doxorubicin modulated clock genes and cytokines in macrophages extracted from tumor-bearing mice. Cancer Biol Ther 2020; 21: 344-53.

[19]

Catanzaro E, Beltrán-Visiedo M, Galluzzi L, Krysko DV. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors. Cell Mol Immunol 2025; 22: 24-39.

[20]

Yang L, Xu J, Xie Z, Song F, Wang X, Tang R. Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo . Asian J Pharm Sci 2021; 16: 762-71.

[21]

Wang Y, Ye H, von Arx D, Li Y, Wang Y, Mesot A, et al. Magnetic continuum soft robot-driven precise delivery of prodrug nanoassemblies for gastric cancer chemo-immunotherapy. Asian J Pharm Sci 2025; 20: 101103.

[22]

Kim J, Shim MK, Yang S, Moon Y, Song S, Choi J, et al. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance. J Control Release 2021; 330: 920-32.

[23]

Shim MK, Yang S, Park J, Yoon JS, Kim J, Moon Y, et al. Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity. J Nanobiotechnol 2022; 20: 436.

[24]

Shim N, Jeon SI, Yang S, Park JY, Jo M, Kim J, et al. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy. Biomaterials 2022; 289: 121806.

[25]

Kim J, Shim MK, Cho YJ, Jeon S, Moon Y, Choi J, et al. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials 2021; 279: 121189.

[26]

Yang S, Shim MK, Kim WJ, Choi J, Nam GH, Kim J, et al. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials 2021; 272: 120791.

[27]

Shim MK, Park J, Yoon HY, Lee S, Um W, Kim JH, et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. J Control Release 2019; 294: 376-89.

[28]

Li Y, Li L, Jin Q, Liu T, Sun J, Wang Y, et al. Impact of the amount of PEG on prodrug nanoassemblies for efficient cancer therapy. Asian J Pharm Sci 2022; 17: 241-52.

[29]

Huang Y, Lin Y, Li B, Zhang F, Zhan C, Xie X, et al. Combination therapy to overcome ferroptosis resistance by biomimetic self-assembly nano-prodrug. Asian J Pharm Sci 2023; 18: 100844.

[30]

Song L, Qiu Q, Ju F, Zheng C. Mechanisms of doxorubicin-induced cardiac inflammation and fibrosis; therapeutic targets and approaches. Arch Biochem Biophys 2024; 761: 110140.

[31]

Xu S, Liu C, Zang S, Li J, Wang Y, Ren K, et al. Multifunctional self-delivery micelles targeting the invasion-metastasis cascade for enhanced chemotherapy against melanoma and the lung metastasis. Asian J Pharm Sci 2021; 16: 794-805.

[32]

Jadapalli JK, Wright GW, Kain V, Sherwani MA, Sonkar R, Yusuf N, et al. Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium. Am J Physiol Heart Circ Physiol 2018; 315: H1091-100.

[33]

Kim Y, Kim J, Jeong JH, Kim I, Shim N, Yoo H, et al. Cancer-specific and pro-apoptotic PEGylated liposomes containing SMAC-mimetic doxorubicin prodrug for safe high-dose delivery in pancreatic cancer. Adv Healthc Mater 2024; 13: e02018.

[34]

Cui Y, Miao Y, Cao L, Guo L, Cui Y, Yan C, et al. Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity. Nat Commun 2023; 14: 5740.

[35]

Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9: 338-50.

[36]

Kim J, Shim MK, Moon Y, Kim J, Cho H, Yun WS, et al. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy. J Nanobiotechnol 2024; 22: 109.

[37]

Yee PP, Li W. Tumor necrosis: a synergistic consequence of metabolic stress and inflammation. Bioessays 2021; 43: e2100029.

[38]

Li H, Wang Z, Chen Z, Ci T, Chen G, Wen D, et al. Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis. Nat Commun 2021; 12: 2773.

PDF (3715KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉